Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Riociguat

Drug and asset intelligence for Riociguat with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Recent signals(1)

ClinicalJune 18, 2026

Study on Riociguat's Impact on Right Heart Function in PAH and CTEPH

A clinical study is underway to assess the effects of riociguat on right ventricular size and function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Riociguat

Monitor the study's outcomes and any subsequent publications or presentations that detail the findings.

June 18, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology →
Cardiology · PAH →
PAH →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.